Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A-002: Phase II data

In the double-blind, international Phase II PLASMA trial, A-002 considerably reduced secretory PLA2

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE